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One of the most pressing global health problems is that there is a mismatch between the health research and
development (R&D) that is needed and that which is undertaken. The dependence of health R&D on market
incentives in the for-profit private sector and the lack of coordination by public and philanthropic funders on
global R&D priorities have resulted in a global health R&D landscape that neglects certain products and
populations and is characterised, more generally, by a distribution that is not ‘needs-driven’. This article
provides an overview of the mismatch, its causes, and solutions.
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T
he mismatch between the health research and
development (R&D)1 that is needed and that
which is undertaken was first demonstrated in
1990, when it was shown that less than 10% of global
health research expenditure was spent on the health
problems of developing countries, which then represented
more than 90% of the world’s burden of preventable
mortality (Fig. 1) (14). This disparity later became well
known as the ‘10/90-gap’. The nature of the 10/90-gap has
changed substantially since 1990: the distribution of the
global disease burden has changed (5); overall global
funding for health R&D has increased from 30 billion
USD in 1986 to 240 billion USD in 2010 (6); there are
many more and new types of actors involved in health
R&D (79); and avariety of new approaches to innovation
have been suggested and tested in recent years, and
continue to be developed, to encourage action on
previously neglected areas of health R&D (10). However,
even though the nature of the 10/90-gap has changed since
1990, the gap itself very much remains to this day (6).
The 10/90-gap is a prominent expression of a broader
problem which is better described as one of ‘neglected
populations’ (10). This neglect can be seen in the lack of
R&D for diseases that predominantly affect developing
countries (the ‘neglected diseases’) (11, 12), in the lack of
R&D that addresses the specific needs of developing
countries in relation to diseases with a global incidence,
and in the lack of development of affordable medicines
for all (10). But the problem of neglect extends beyond
the developing world, as becomes clear from the global
lack of R&D for new antibiotics (13), appropriate
children’s medicines (and other products) (14, 15), and
orphan diseases (7, 16). In addition to neglected popula-
tions, there are neglected products. R&D is generally
more focused on the development of drugs and vaccines
than on the development of diagnostics or platform
technologies (technologies that can potentially be applied
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1R&D is defined by the Organisation for Economic Co-operation
and Development (OECD) as: ‘Research and experimental
development comprise creative work undertaken on a systematic
base in order to increase the stock of knowledge, including
knowledge about man, culture, and society, and the use of this
knowledge to devise new applications’ (1). R&D is generally
subdivided into basic research, applied research, and experimental
development. Health R&D includes fields such as epidemiology,
health services and health systems research, and health-related social
research (13).
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to different diseases and products) (11, 17). Moreover,
for specific diseases, some products are neglected in terms
of R&D, whereas others are not (18).
Besides the discrete distinction between neglected and
non-neglected areas of health R&D, there is a broader
issue with the global distribution of health R&D as part of
the mismatch. ‘Needs-driven’ R&D is not necessarily
characterised by a linear relationship between disease
burden and R&D funding, because burden of disease is
just one of the factors that determine health R&D need
(see Box 1 for what determines health R&D need) (11, 19).
In assessing health R&D needs, it is necessary to be
specific about the knowledge and products that are needed
for each health problem and to take into account
differences in need between different populations (18).
However, on the presumption that R&D funding is
responsive to the scale of a health problem, a degree of
correlation between the burden of a health problem and
Fig. 1. The figure from the report of the Commission on Health Research for Development that formed the basis for the term
‘10/90-gap’ (reprinted by permission of Oxford University Press, USA) (4).
Table 1. Distribution of global health R&D funding across neglected diseases
Disease
Global R&D funding 2011
(million US$)
Global BoD
(million DALYs)
Global R&D funding in US$/
global DALY
HIV 1,117 81.5 13.7
Malaria 596 82.7 7.2
Tuberculosis 584 49.4 11.8
Dengue 249 0.8 301.7
Diarrhoeal diseases 169 89.5 2.0
Kinetoplastids 142 4.4 32.0
Bacterial pneumonia and meningitis 107 68.0104.9a 1.01.6
Helminths (worms and flukes) 90 12.3 7.3
Salmonella infections 48 17.1 2.8
Trachoma 10 0.3 31.1
Leprosy 8 0.006 1400.9
Buruli ulcer 6 NAb 
Rheumatic fever 1 10.1 0.1
Notes: Table is based on Table 2 from the G-FINDER report 2012, which reports on global R&D funding for 31 neglected diseases (12).
‘Neglected diseases’ are defined in this report as diseases that disproportionally affect people in developing countries, for which there is a
need for new products, and for which there is market failure. The list of 31 diseases includes HIV, tuberculosis and malaria, and thus
adheres to a different definition of neglected diseases than WHO (24). Burden of disease (BoD) data are from the Global Burden of Disease
(GBD) study 2010 (25). DALYsdisability-adjusted life years.
aGlobal BoD for bacterial pneumonia and meningitis is displayed as a range because ‘other LRIs’ and ‘other meningitis’ in the GBD study
2010 were not sub-specified into viral or bacterial pathogens. The lower limit represents the BoD without the ‘other’ categories, while the
upper limit includes the ‘other categories’.
bGlobal BoD data for buruli ulcer were not available.
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R&D funding can be expected (11, 19, 2023). Working
from this presumption provides us with a crude approach
to assessing the global distribution of health R&D funding
(as was done with the 10/90-gap) (4). Within the area of
neglected diseases, the Global Funding of Innovation for
Neglected Diseases (G-FINDER) reports have shown that
of 31 neglected diseases, some are more neglected than
others (12). There are three ‘top tier’ diseases which each
receive one-third to one-sixth of the total global neglected
disease R&D funding, a number of ‘second tier’ diseases
which each receive 18% of total funding, and several
‘third tier’ diseases, which are the most poorly funded and
receive less than 0.5% of the global funding each (12).
Table 1 shows the neglected diseases from the most recent
G-FINDER report in terms of funding and in terms of
global burden of disease. In interpreting this table, it is
important to remember that health R&D need depends on
more than burden of disease (Box 1). Nonetheless, the
findings from G-FINDER make clear the variations in
R&D investments for these diseases. Moreover, the G-
FINDER reports have shown that R&D investments for a
particular disease are not necessarily allocated towards
developing the knowledge or products that are most
needed for that disease (26). It is concluded that ‘R&D
funding is often poorly matched with disease needs and
scientific and technical possibilities’ (26).
Although there are also indications in other areas, such
as R&D for orphan drugs, that there are some diseases
that are more neglected than others (16), analyses such
as the G-FINDER reports, which aggregate all global
funding towards a set of diseases, are rare. Because only
few funders publicly report disaggregated statistics on
health R&D expenditures, and because of a lack of
uniformity in the use of R&D classification systems
across different funders, such analyses are complex and
resource-intensive (27). However, when we look at
individual R&D funders’ investment portfolios, marked
variations in funding for similar diseases also become
apparent. Brower argued in 2005 that ‘research funding
is not necessarily allocated to those who need it most’
by showing the variation in R&D funding for different
diseases by the US National Institutes of Health (NIH)
(28). Table 2 shows an updated list of US NIH R&D
funding for different cancers in the US and makes clear
the variation in R&D funding per US disability-adjusted
life year (DALY) for these diseases.
Looking at research investments is only one way of
measuring what R&D is being undertaken. Other R&D
indicators can also be reviewed, such as the number of
research articles or ongoing clinical trials (6, 19, 23, 31
34). By doing so, Nwaka et al., with regard to health
R&D in Africa, recently showed that ‘diseases dispro-
portionately affecting Africa are under-prioritised’ (31).
Table 3 is based on some of their results and makes clear
Box 1. What is ‘health R&D need’?
What determines whether there is a need for health
R&D? To determine health R&D need it is neces-
sary to first evaluate which health problems exist
that cause a burden of disease (Fig. 2). The more
prominent the health problem, the larger the poten-
tial impact of R&D. The scale of different health
problems is regularly assessed as part of the Global
Burden of Disease studies (75, 76). Second, it is
necessary to determine the need for new knowledge
and/or products (including devices, medicines, vac-
cines, procedures, and systems (77)) for a given
health problem (12, 3638). Finally, to determine
health R&D need, we must also take into account
what health R&D is already being undertaken (19,
45, 7880).
With all these steps it is critical to be specific and
account for potential differences in health R&D
need between different populations, such as geogra-
phical regions, age groups, and socioeconomic sub-
groups (11, 18, 81, 82).
Fig. 2. Health R&D need is determined by: (A) existing
health problems, (B) the need for new knowledge and
products, and (C) the health R&D that is already being
undertaken.
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for the five diseases with the highest burden from Table 1
that the variations in numbers of African publica-
tions and African clinical trials roughly correspond to
the variations in global R&D funding. In another
example, Dear et al. show that variations in the R&D
that is conducted for different cancers exist in other
countries too, by demonstrating that in Australia ‘four
of the five cancers that result in the greatest burden of
disease had relatively few clinical trials’ (33).
Causes
The problem is, then, that the health R&D that is
undertaken globally is not ‘needs-driven’. The global
landscape of health R&D shows gaps; there are neglected
populations and products. Besides the discrete distinction
between neglect and non-neglect, there are marked
variations in the amount of R&D that is conducted for
different health problems. Finally, the R&D that is
undertaken for a particular health problem does not
always match the knowledge or product development
that is most needed for that problem. What has caused
this mismatch between the health R&D that is needed
and that which is undertaken?
A rational approach to establishing and funding
a global agenda for health R&D is illustrated in Box 2.
In reality, there are problems with every step of this
approach, together forming the reasons that the mis-
match exists.
First, there is no system to comprehensively, system-
atically, and periodically map what health R&D is needed
globally (step 1) (35). Health R&D needs, as detailed in
Box 1, are determined by the burdens of existing health
problems, by the need for new knowledge and products,
and by the R&D that is already being undertaken.
Although substantial progress has been made in evaluat-
ing the burdens of existing health problems (25, 29),
the need for new knowledge and products is only assessed
on an ad-hoc basis and for a selected number of diseases
(12, 3638). Our knowledge of what health R&D is being
conducted, where it is being conducted, by whom and
how, is also very limited (19, 27). Moreover, there is
currently no accepted approach for comparing health
R&D needs across different health problems (35).
Second, although health R&D priorities are regularly
established for specific diseases and countries, there is
currently no system to facilitate the prioritisation of
all health R&D needs and the formulation of ‘best buys’
in health R&D globally (step 2) (39, 40).
Finally, there are problems with realising a coordinated
response to established global priorities for health R&D
(steps 3 and 4). The current global health R&D system
relies strongly on market incentives. About 60% of all
health R&D funding comes from the for-profit private
sector (6). However, when market incentives drive in-
novation, R&D that is profitable will be preferred, with
Table 2. Distribution of US National Institutes of Health
(NIH) funding across cancers
Disease
US NIH R&D
funding 2011
(million US$)
US BoD
(thousand
DALYs)
US NIH R&D
funding in
US$/US DALY
Prostate cancer 284 225 1262.0
Cervical cancer 143 114 1253.7
Breast cancer 715 612 1167.4
Ovarian cancer 138 145 951.8
Colorectal cancer 313 542 577.4
Liver cancer 74 138 537.0
Uterine cancer 40 75 530.0
Pancreatic cancer 112 238 471.1
Lung cancer 221 1,248 177.1
Notes: Table is based on Table 1 from Brower (2005) (28). US
burden of disease (BoD) Data were derived from the WHO Global
Burden of Disease (GBD) report from 2004 (29) (2010 GBD
country data will not be released until September 2013). US NIH
funding data were derived from NIH Research Portfolio Online
Reporting Tools (RePORT) (30).
DALYsdisability-adjusted life years.
Table 3. Distributions of research articles and clinical trial research across five neglected diseases in Africa
Number of articles with at least one African
author/million African DALY
Number of trials recruiting in Africa/
million African DALY
Diarrhoeal diseases 9.1 0.2
Lower respiratory infections and meningitis 10.6 0.5
Malaria 59.7 6.6
HIV 53.6 4.5
Tuberculosis 82.8 4.1
Notes: To demonstrate how the distribution of R&D can be measured using different R&D indicators, numbers of African research articles
and African clinical trials are related to African burden of disease for the five diseases with the highest burden of disease in Table 1.
Numbers were calculated from Nwaka et al. (2010) (31).
DALYsdisability-adjusted life years.
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the neglect of populations and products that are not
profitable as a result (10, 11). Market incentives even
drive the development of products that may be profitable
but that offer little or no additional therapeutic value
(‘me-too’ drugs) (10). Furthermore, few measures exist to
ensure that products are affordable, which is an ever-
present challenge for universal access to medicines when
one considers that the great majority of the global burden
of disease is carried by populations in developing
countries (25, 29). Finally, a lack of open innovation is
inherent to a competitive, privatised system and consti-
tutes an impediment to the efficiency and ethicality of
the R&D system (10). This was recently demonstrated
by the reluctance of pharmaceutical companies, with
one exception (GlaxoSmithKline), to join the AllTrials
campaign (an initiative that calls for all clinical trials to
be registered and all trial results to be reported) (41).
Public and philanthropic donors are responsible for
the remaining 40% of all health R&D funding (6). In the
area of neglected disease R&D, where more than 80%
of R&D funding is allocated by these funders, the
G-FINDER reports consistently show under-funding of
priority areas of R&D and high-burden diseases (11, 12).
How can it be that such gaps remain when public and
philanthropic funders distribute the majority of funding?
One important reason is that there is not yet an
accepted system of accountability for global health
R&D needs. It is becoming increasingly recognised that
the outputs of health R&D should be viewed as global
public goods, meaning that all knowledge and products
resulting from health R&D should be adapted and
accessible to a global population of end users and
that funding health R&D should be a globally shared
burden (42). Yet, currently, there is no global governance
arrangement that makes explicit the shared accountabil-
ity that such views imply. In the absence of a concrete
shared vision of accountability, the Bamako call to action
on research for health suggests that in the current system
all funders of health R&D are jointly responsible to
‘better align, coordinate, and harmonise the global health
research architecture’ (43). However, in practice there are
problems with regard to the degree to which these funders
are accountable for global health R&D needs. The public
and philanthropic health R&D funding landscape is
diverse and includes national public funders of health
R&D (such as health ministries or government research
organisations), distributors of official development as-
sistance (ODA) (such as government development or
foreign affairs ministries), multilateral funding agencies,
and philanthropic funders of health R&D (7, 12).
National public funders of health R&D have often been
established under national laws, have nationally focused
remits, and are accountable to the parliament of the
country they are based in. Hence, it is questionable
whether they can be expected to fund health R&D that
is globally relevant, but not of relevance to the country
they are based in. Distributors of ODA do often have a
global focus, but their contributions to overall global
health R&D are relatively small as compared to funding
by national public funders of health R&D (neglected
disease R&D funding in the United States from 2000
to 2010, was funded predominantly by the NIH (87%)
and much less so by the US Agency for International
Development (6%) and the US Department of Defense
(6%) (12, 44, 45)). The same is true for multilaterals
(11, 12). In addition, multilaterals are often dependent on
Box 2. A rational approach for establishing and funding a global health R&D agenda.
A rational approach for establishing and funding a global health R&D agenda consists of four steps
(7, 11, 39):
1) Identify health R&D needs  What are the gaps in the health R&D landscape
that need to be addressed?
For such identification we need (see Box 1): R&D needs
R&D priorities
R&D agenda
a) Evaluation of existing health problems;
b) Evaluation of need for new knowledge and products;
c) Evaluation of health R&D that is already being undertaken.
2) Prioritise  Which health R&D needs, if addressed,
would result in the highest health return on investment?
Decision criteria:
a) Expected health benefit
b) Expected costs
c) Expected feasibility
3) Coordinate  coordinate among funders to agree on a common
health R&D agenda.
4) Fund  fund the health R&D agenda.
The mismatch between needed and undertaken health R&D
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earmarked funding (46), and several multilaterals have
remits that are limited to a specific set of diseases.
Philanthropic funders of health R&D may also have a
global focus, but given that they are privately funded,
their accountability for global health R&D needs is, at
best, uncertain (21). Tensions between global and na-
tional level priorities that arise because of the increasingly
globalised nature of R&D, while most research funding is
provided at a national level, are not unique to health (47).
Another important reason for the persistent nature
of gaps in the global health R&D landscape is the lack of
coordination by public and philanthropic funders on
health R&D priorities. Given the fragmented funding
landscape, enhanced coordination between funders
on shared R&D priorities is greatly needed. However,
such coordination currently only occurs selectively in
particular areas (7, 40). There is no global ‘forum’ where
funders comprehensively and periodically discuss priority
health R&D needs and how to address those needs in a
coordinated manner (40).
Finally, R&D funding allocation decisions by public
and philanthropic funders, whether they have a national
or a global remit, may be influenced by factors other than
the need for health R&D (11, 20, 28, 4851). Such factors
include: the testimonials of patient advocacy groups or
organisations with disease-specific mandates and advo-
cacy and fundraising activities  ‘the squeaky wheel gets
the grease’, as Brower suggests (11, 16, 28, 48); the
presence of policy frameworks and funding mechanisms
that prioritise specific diseases (11, 20); preferences of
researchers (with most funders a large part of the re-
search that is funded is investigator-initiated and some
do not prioritise research areas at all) (28, 48, 49), to
which the existence of trusted R&D groups, the institu-
tionalisation of research topics, the attractiveness of
research results, and the potential for publication con-
tribute (11, 49, 52); the national values, interests, and
political dynamics of the country in which the funder is
based (20, 48, 50, 51); global values and political
dynamics (20); community and media attention (28, 48,
49); and funder perceptions, preferences, and account-
abilities (11, 48, 50). Given these diverse influences, there
is a strong need for transparency from public and
philanthropic health R&D funders on precisely what
health R&D they fund and what their decision mechan-
isms are for funding allocation (21, 40). Funders them-
selves recognise the need for such transparency, as
becomes clear from a recent joint statement from several
large health R&D funders on the importance of shar-
ing research data (53). Unfortunately, individual funders
that provide publicly accessible statistics on past funding
for different health and research categories are still an
exception rather than a rule, and funders continue to
apply a kaleidoscope of different research classification
systems, making aggregate analysis of what funders fund
exceedingly problematic (27).
Solutions
The mismatch between the health R&D that is needed
and the R&D that is undertaken has proven persistent
over the past decades. Yet, solutions to this problem are
available. The Consultative Expert Working Group on
Research and Development: Financing and Coordination
(CEWG) (7), an expert working group established by the
World Health Assembly in 2010, released an extensive
report in 2012 which provides recommendations for how
to systematically identify global health R&D priorities
and ensure that these are addressed in a coordinated
manner. The starting point for realising this is described
to be the establishment of a Global Observatory on
Health R&D (6, 7, 19).
The mission of an Observatory is envisioned to include
the mapping of health R&D needs, with the goal of
establishing clarity on R&D priorities (‘best buys’), and
the bringing together of health R&D funders to facilitate
coordinated action on a shared R&D agenda. If these
goals are to be reached, lessons would have to be learned
from the shortfalls of the Global Forum for Health
Research, an organisation with a similar mandate which
was recently discontinued. Two lessons are of particular
importance to the challenges that an Observatory could
be faced with. First, although the Global Forum estab-
lished a process for continuous monitoring of global
investments in health R&D (44), it never succeeded in
conducting a comprehensive mapping of the needs for
new knowledge and products. Arguably, this is the most
important step of any priority-setting process for health
R&D and would need to be a focus of an Observatory
(35, 39). Second, the most effective way to ensure that
‘best buys’ in health R&D are indeed funded would be to
link an Observatory to a pooled funding mechanism,
akin to the Global Health Research Fund once suggested
by the Commission on Macroeconomics and Health (54).
Such a fund could disperse funding to public, private,
or publicprivate partnership research entities in areas
of identified priority health R&D need (7). Should this
prove unfeasible, then an alternative would be to bring
together funders of health R&D to galvanise coordinated
action on a shared R&D agenda (4, 7, 40). The Global
Forum was established precisely to be a forum for such
discussion, but never succeeded in actually bringing
funders together to discuss ‘best buys’ in health R&D.
To prevent a similar course of events with an Observa-
tory, it will be essential to generate broad support for this
new platform and to work together with key funders of
health R&D in giving rise to the final shape and form
of an Observatory (55). One way to do this would be to
learn or even build from existing models of funder
collaboration that have proven to be successful, such as
Roderik F. Viergever
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the European and Developing Countries Clinical Trials
Partnership (56) and ESSENCE on Health Research
(Enhancing Support for Strengthening the Effectiveness
of National Capacity Efforts) (57).
Strengthening national health research systems, in
particular in those countries with the largest burden of
disease, was already noted as being of particular im-
portance to correcting the 10/90-gap in 1990 by the
Commission on Health Research for Development (4).
Their report lead to the establishment of the Council on
Health Research for Development (COHRED) in 1993,
an organisation whose mission is to ‘improve health,
equity, and development by supporting countries to
develop strong research and innovation systems’ (58).
Yet, two decades later, despite significant efforts to
improve countries’ health research systems, by COHRED
(59) and others (60), this still constitutes a challenge of
pressing priority (60). An envisaged additional advantage
of an Observatory would be that it could provide an
impetus for national health research system strengthen-
ing. It could do so by stimulating the development of
good practices and standards in health research, by
providing support for building capacity for health R&D
in developing countries, by producing analyses to inform
national R&D portfolio management, and by creating
a platform to convene stakeholders (6, 55).
The pharmaceutical industry has developed more
expertise with technologies for the conversion of basic
scientific discoveries into new therapies than the public
sector and the involvement of the for-profit private sector
is thus of major importance in creating solutions to the
mismatch (36). Many different approaches for engaging
the for-profit private sector in targeting unprofitable
R&D and for delinking the price of health R&D from
its cost have been proposed and tested in recent years (10).
Examples are product development partnerships, which
have proven particularly effective for developing new
products for neglected diseases (10, 45); other public
private partnerships, such as those recently announced
by both the European Union and the United States
that will aim to develop new antibiotics in the face of
increasing antibiotic resistance (61, 62); economic incen-
tives established through legislation, which have shown
to be effective for stimulating R&D for paediatric
medicines and orphan drugs (although only in part,
with both orphan drugs and paediatric medicines con-
cerns have been raised about using economic incentives,
since the R&D that is stimulated through such measures
remains driven by market incentives rather than by need)
(14, 16, 63, 64); and different kinds of prizes and grants
to companies, which are considered to be particularly
effective for stimulating health R&D of relevance to
developing countries (7).
Besides improving the prioritisation of health R&D
needs, facilitating the coordination of public and philan-
thropic funders, strengthening national health research
systems, and engaging the for-profit private sector, it
will be necessary to increase access to research results
and to improve research collaboration (through open
approaches to R&D, equitable licensing, and patent
pools) (7).
Finally, there is a need to gather these different
measures under the umbrella of a concerted mechanism
through the establishment of a global framework or
convention on health R&D (7, 10) (the World Health
Organization (WHO) has the option to create legally
binding conventions on the basis of a two-thirds majority
vote of its Member States, but has only done so once
(65)). A framework or convention would provide the
global governance framework to secure the nature of
health R&D as a global public good, making explicit the
globally shared responsibilities for addressing global
health R&D needs and thus raising the financial
resources needed to realise such sizeable changes to the
global health R&D system (7, 42, 66). Notably, such
funds would allow for the realisation of a pooled funding
mechanism linked to an Observatory, providing an
effective, coordinated, and sustainable source of funding
for identified health R&D priorities (7, 67). The establish-
ment of a framework or convention has been a much
discussed topic in recent years (7, 10). Because countries
would be expected to contribute financially based on
their level of development (7, 42), while the R&D output
would mainly benefit populations in developing coun-
tries, it has been a much contested proposal on which
nations have stood divided. At the most recent World
Health Assembly of May 2013, discussion on a frame-
work or convention was postponed until 2016 (68, 69).
This is a regrettable outcome after more than two decades
of negotiations and reports by several expert working
groups, who have all made sensible and rational sugges-
tions to improve the world’s health R&D system, but
have been met with little action (4, 7, 7073).
Although discussion on a framework or convention
was postponed, the establishment of a Global Observa-
tory on Health R&D was enacted at the most recent
World Health Assembly (68, 69). Furthermore, WHO
was requested to review possibilities for coordinating and
financing global health R&D priorities (35, 67, 69) and
to facilitate the implementation of several health R&D
demonstration projects to address identified gaps that
disproportionately affect developing countries (69, 74).
These plans alone are not enough to address the
substantive mismatch between the health R&D that is
needed and that which is undertaken. Still, they consti-
tute an important step forward and, looking ahead to
the World Health Assembly in 2016, present an oppor-
tunity for demonstrating the value of more far-reaching
changes to the global governance framework for health
R&D. It is important that WHO takes immediate action
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to demonstrate that value, in particular through coordi-
nating the selection and implementation of the health
R&D demonstration projects.
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